LLD therapy research
August 19, 2014
NEW research designed to assess
the level of provision of lipidlowering
drugs (LLD) to Australian
high risk patients, published in
the MJA, has demonstrated that
a large proportion of concession
card holders at high coronary risk,
especially those in middle age
with coronary heart disease and
multiple risk factors, are being
appropriately prescribed LLD.
Data on 276,212 patients defined
as being at high coronary risk
was evaluated as to the level of
treatment provided with LLD, in this
study defined as statins, fibrates or
ezetimibe.
CLICK HERE to access the paper.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Aug 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Aug 14